{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003882","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.186114+00:00","generated_at":"2026-06-07T02:23:37.488697+00:00","sec_items":["1.01","2.02","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Solid Biosciences raises $108.9M in private placement; preliminary cash $123.9M","bullets":["Gross proceeds ~$108.9M from 16,973,103 shares at $5.53/share and 2,712,478 pre-funded warrants at $5.529 each.","Net proceeds ~$104.1M after fees; closing expected January 11, 2024.","Preliminary unaudited cash, equivalents and securities of $123.9M as of Dec 31, 2023 (excluding PIPE proceeds).","Clinical milestones: SGT-003 safety update mid-2024, initial data Q3 2024; SGT-501 IND submission Q1 2025.","Investors include Perceptive Advisors, Adage Capital, Deerfield, Invus, Janus Henderson, Vestal Point, Bain Capital, RA Capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003882","json":"https://secwatch.observer/filing/0001193125-24-003882.json","markdown":"https://secwatch.observer/filing/0001193125-24-003882.md","text":"https://secwatch.observer/filing/0001193125-24-003882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312524003882/0001193125-24-003882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312524003882/d690167d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:23:37.488697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e41f03a48523a3b9cb7505de29ce8b646239270","claim":"Solid Biosciences Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, the Company disclosed in the Presentation that it expects to report cash, cash equivalents and available-for-sale securities of approximately $123.9 million as of December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312524003882/0001193125-24-003882-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"65b108a7f9d8119860bf48eed74c0f322cc45ddd","claim":"Solid Biosciences Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at aggregate gross proceeds from the Private Placement of approximately $108.9 million (effective 2024-01-08).","evidence_excerpt":"On January 8, 2024, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 16,973,103 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.53 per share, and, to one Investor in lieu of Shares, pre-funded warrants to purchase 2,712,478 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.529 per Pre-Funded Warrant (the “ Private Placement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312524003882/0001193125-24-003882-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"aggregate gross proceeds from the Private Placement of approximately $108.9 million"},{"label":"Effective","value":"2024-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}